DNA Methylation in Ovarian Cancer Susceptibility

Reid, Brett M.; Fridley, Brooke L.

doi:10.3390/cancers13010108

Cited by 11 publications

(6 citation statements)

References 90 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, our study also revealed that the abnormally high expression of ARRDC2 may be associated with abnormal hypomethylation of DNA, as shown in Supplementary Figures S2A–D . Numerous studies have confirmed that DNA methylation in epigenetics plays an important role in the malignancy, metastasis and recurrence of ovarian cancer ( Papakonstantinou et al, 2020 ; Reid and Fridley, 2020 ). Epigenetic regulation, represented by DNA methylation, is essential for the regulation of oncogenes ( Oliveira et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer

Zhang

Liu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: The abnormal expression of α-arrestin protein family plays a key regulatory role in the occurrence and development of many cancers, including colorectal cancer and cervical cancer, and is inseparable from changes in the tumor immune microenvironment. However, the role of ARRDC2, an important member of this family, in the malignant biological process of ovarian cancer (OC) has not been reported, and its role in the change of the immune microenvironment is also unknown.Methods: In this study, HPA, TCGA, GEO and other databases were used to explore the role of ARRDC2 in the prognosis assessment of ovarian cancer. Then, GO, KEGG analysis and GSEA analysis of the biological processes and cell signaling pathways that ARRDC2 may be involved in activated or inhibited. In addition, the TIMER and TISIDB database were used to conduct in-depth research on the role of ARRDC2 in the change of the immune microenvironment of ovarian cancer. The CMap database explored and screened drugs that may be used for treatment. Through cell transfection, CCK-8, Ki-67 immunofluorescence, wound healing, transwell and clone formation assay, the effect of ARRDC2 knockdown on the malignant biological behavior of OC cells were explored.Results: There were significant differences between OC and ARRDC2 mRNA and protein levels. High ARRDC2 expression level is associated with poor overall survival and can be used as an independent prognostic factor. Interestingly, ARRDC2 expression is positively correlated with B cells, Neutrophils, Dendritic cells and CD8+ T cells, signifying that ARRDC2 may be related to infiltration of immune cells. ARRDC2 and its co-expressed genes are enriched in cell signaling pathways related to the immune system. We explored two possible drugs for the treatment of ovarian cancer. Finally, the results of in vitro experiments indicated that knockdown of ARRDC2 may inhibit malignant phenotypes such as proliferation and migration of OC cells.Conclusion: The differentially expressed ARRDC2 may be a potential prognostic indicator and can be used as a novel biomarker for exploring the immune microenvironment of ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer

Zhang

Liu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…The rapid development of omics sequencing technology has allowed researchers to analyze the mechanism of OV progression through large-scale gene expression data and clinical information. Aberrant DNA methylation is the most widely studied deregulatory epigenetic mechanism in tumors [ 18 ], making it valuable in evaluating OV patients' prognoses.…”

Section: Discussionmentioning

confidence: 99%

Integration of Transcriptome and Epigenome to Identify and Develop Prognostic Markers for Ovarian Cancer

Cao

2022

Journal of Oncology

View full text Add to dashboard Cite

DNA methylation is a widely researched epigenetic modification. It is associated with the occurrence and development of cancer and has helped evaluate patients’ prognoses. However, most existing DNA methylation prognosis models have not simultaneously considered the changes of the downstream transcriptome. Methods. The RNA-Sequencing data and DNA methylation omics data of ovarian cancer patients were downloaded from The Cancer Genome Atlas (TCGA) database. The Consensus Cluster Plus algorithm was used to construct the methylated molecular subtypes of the ovary. Lasso regression was employed to build a multi-gene signature. An independent data set was applied to verify the prognostic value of the signature. The Gene Set Variation Analysis (GSVA) was used to carry out the enrichment analysis of the pathways linked to the gene signature. The IMvigor 210 cohort was used to explore the predictive efficacy of the gene signature for immunotherapy response. Results. We distinguished ovarian cancer samples into two subtypes with different prognosis, based on the omics data of DNA methylation. Differentially expressed genes and enrichment analysis among subtypes indicated that DNA methylation was related to fatty acid metabolism and the extracellular matrix (ECM)-receptor. Furthermore, we constructed an 8-gene signature, which proved to be efficient and stable in predicting prognostics in ovarian cancer patients with different data sets and distinctive pathological characteristics. Finally, the 8-gene signature could predict patients’ responses to immunotherapy. The polymerase chain reaction experiment was further used to verify the expression of 8 genes. Conclusion. We analyzed the prognostic value of the related genes of methylation in ovarian cancer. The 8-gene signature predicted the prognosis and immunotherapy response of ovarian cancer patients well and is expected to be valuable in clinical application.

show abstract

“…Research into ovarian carcinomas has recognized characteristic hypomethylation in Sat2 [ 244 , 245 ]. Moreover, ovarian cancer cells were found to have a reduced LINE-1 methylation phenotype corresponding to the global methylation and hypermethylation of specific gene sites such as the BRCA1 promoter [ 246 , 247 , 248 ].…”

Section: Egcg Treatment In Malignant Gynecological Diseasesmentioning

confidence: 99%

Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms

Włodarczyk,

Ciebiera,

Nowicka

et al. 2024

Nutrients

View full text Add to dashboard Cite

The most common malignant gynecologic diseases are cervical, uterine, ovarian, vaginal, and vulvar cancer. Among them, ovarian cancer causes more deaths than any other cancer of the female reproductive system. A great number of women suffer from endometriosis, uterine fibroids (UFs), adenomyosis, dysmenorrhea, and polycystic ovary syndrome (PCOS), which are widespread benign health problems causing troublesome and painful symptoms and significantly impairing the quality of life of affected women, and they are some of the main causes of infertility. In addition to the available surgical and pharmacological options, the effects of supporting standard treatment with naturally occurring compounds, mainly polyphenols, are being studied. Catechins are responsible for the majority of potential health benefits attributed to green tea consumption. Epigallocatechin gallate (EGCG) is considered a non-toxic, natural compound with potential anticancer properties. Antioxidant action is its most common function, but attention is also drawn to its participation in cell division inhibition, apoptosis stimulation and epigenetic regulation. In this narrative review, we describe the role of EGCG consumption in preventing the development of benign reproductive disorders such as UF, endometriosis, and PCOS, as well as malignant gynecologic conditions. We discuss possible epigenetic mechanisms that may be related to the action of EGCG.

show abstract

DNA Methylation in Ovarian Cancer Susceptibility

Cited by 11 publications

References 90 publications

A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer

A Potential Indicator ARRDC2 Has Feasibility to Evaluate Prognosis and Immune Microenvironment in Ovarian Cancer

Integration of Transcriptome and Epigenome to Identify and Develop Prognostic Markers for Ovarian Cancer

Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases—Focus on Epigenetic Mechanisms

Contact Info

Product

Resources

About